# Assessment of long-read strategies for the enrichment of clinically relevant breakpoints in lymphomas: towards a diagnostic implementation

**Authors:** Filip Pardy, Kamila Reblova, Hana Svozilova, Boris Tichy, Sarka Pospisilova, Jana Kotaskova, Veronika Navrkalova

PMC · DOI: 10.1007/s00277-026-06754-2 · 2026-01-21

## TL;DR

The study compares different long-read sequencing methods to detect genetic breakpoints in lymphomas, aiming to improve diagnostic accuracy and treatment.

## Contribution

A Cas9-based enrichment panel and decision algorithm are proposed for optimal breakpoint detection in clinical lymphoma diagnostics.

## Key findings

- Cas9-mediated enrichment provides superior on-target coverage for densely targeted regions like the IGH locus.
- Adaptive sampling offers higher throughput and flexibility but has limited breakpoint detection capabilities.
- Cas9 excision is a fast and reliable method for detecting canonical translocation partners in clinical samples.

## Abstract

Recurrent chromosomal translocations are hallmarks of many hematological malignancies, including lymphomas and leukemias. Accurate breakpoint detection is essential for diagnostics, treatment optimization, and disease monitoring. Long-read sequencing (Oxford Nanopore Technologies) enables unambiguous mapping and translocation identification. We designed a Cas9-based enrichment panel targeting common translocations in lymphoid malignancies. To accommodate both well-defined and promiscuous translocation partners, we employed single-side and dual-side sequencing strategies. Using well-established lymphoid cell lines, we benchmarked three enrichment approaches: (i) Cas9 read-out, (ii) Cas9 excision with multiplexing, and (iii) adaptive sampling. Cas9-mediated enrichment achieved superior on-target coverage, particularly in densely targeted regions (such as the IGH locus), while single-probe targets showed lower coverage depth. Adaptive sampling offered higher throughput, flexibility, and better pore occupancy, however with limited breakpoint detection. Cas9 excision has been demonstrated as a fast and reliable method to detect canonical translocation partners in clinical lymphoma samples. Our findings indicate that long-read enrichment strategies are suitable for targeting breakpoint hotspots, although the choice of approach depends heavily on the laboratory's specific goal. We propose a decision algorithm for selecting the optimal method based on experimental and clinical needs: Cas9-mediated enrichment suits focused diagnostic intent, while adaptive sampling is preferable for broader research use.

The online version contains supplementary material available at 10.1007/s00277-026-06754-2.

## Linked entities

- **Proteins:** cas9 (type II CRISPR RNA-guided endonuclease Cas9)
- **Diseases:** leukemias (MONDO:0005059)

## Full-text entities

- **Genes:** BCR (BCR activator of RhoGEF and GTPase) [NCBI Gene 613] {aka ALL, BCR1, CML, D22S11, D22S662, PHL}, AICDA (activation induced cytidine deaminase) [NCBI Gene 57379] {aka AID, ARP2, CDA2, HEL-S-284, HIGM2}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, IGH (immunoglobulin heavy locus) [NCBI Gene 3492] {aka IGD1, IGH.1@, IGH@, IGHD@, IGHDY1, IGHJ}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) [NCBI Gene 25] {aka ABL, BCR-ABL, CHDSKM, JTK7, bcr/abl, c-ABL}, IGHD (immunoglobulin heavy constant delta) [NCBI Gene 3495], MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, RUNX1 (RUNX family transcription factor 1) [NCBI Gene 861] {aka AML1, AML1-EVI-1, AMLCR1, CBF2alpha, CBFA2, EVI-1}, BCL6 (BCL6 transcription repressor) [NCBI Gene 604] {aka BCL5, BCL6A, LAZ3, ZBTB27, ZNF51}, KMT2A (lysine methyltransferase 2A) [NCBI Gene 4297] {aka ALL-1, ALL1, CXXC7, GAS7, HRX, HTRX}, IGL (immunoglobulin lambda locus) [NCBI Gene 3535] {aka IGL@}
- **Diseases:** diffuse large B-cell lymphoma (MESH:D016403), hereditary and malignant diseases (MESH:D030342), lymphoid malignancies (MESH:D008223), leukemias (MESH:D007938), B-ALL (MESH:D015452), Pan-cancer (MESH:D009369), acute leukemias (MESH:D015470), oncogenic (MESH:D000074723), B-cell lymphoma (MESH:D016393), B-ALL B-cell acute lymphoblastic leukemia (MESH:D015448), hematological malignancies (MESH:D019337), non-Hodgkin lymphomas (MESH:D008228), AS (MESH:D018489), chronic myeloid leukemia (MESH:D015464), MCL mantle cell lymphoma (MESH:D020522), BL burkitt lymphoma (MESH:D002051), tumorigenesis (MESH:D063646), FL follicular lymphoma (MESH:D008224)
- **Chemicals:** Cas9 (-)
- **Species:** Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** Ramos — Homo sapiens (Human), Burkitt lymphoma, Cancer cell line (CVCL_0597), Maver-1 — Homo sapiens (Human), Mantle cell lymphoma, Cancer cell line (CVCL_1831), NALM-6 — Homo sapiens (Human), Adult B acute lymphoblastic leukemia, Cancer cell line (CVCL_0092), NBD-114 — Homo sapiens (Human), Transformed cell line (CVCL_D326), PROM-114 — Homo sapiens (Human), Chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_XR92), ML-2 — Homo sapiens (Human), Adult acute myeloid leukemia, Cancer cell line (CVCL_1418), JVM-2 — Homo sapiens (Human), Mantle cell lymphoma, Transformed cell line (CVCL_1319), Granta-452 — Homo sapiens (Human), B acute lymphoblastic leukemia, Cancer cell line (CVCL_1817), KCL-22 — Homo sapiens (Human), Chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_2091), DOHH-2 — Homo sapiens (Human), Diffuse large B-cell lymphoma germinal center B-cell type, Cancer cell line (CVCL_1179)

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12823746/full.md

---
Source: https://tomesphere.com/paper/PMC12823746